Evaluating the Role of mpMRI in Prostate Cancer Assessment

Mertan, Francesca; Berman, Rose; Szajek, Kathryn; Pinto, Peter A.; Choyke, Peter L.; Türkbey, Barış

doi:10.1586/17434440.2016.1134311

Cited by 14 publications

(9 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Multiparametrik prostat MRG tetkiklerinde, anatomik sekanslar [T1 ve yüksek çözünürlük-lü T2 ağırlıklı (T2A)] ve fonksiyonel sekanslar [yüksek b değerli difüzyon ağırlıklı görüntüle-me (DAG) ve yüksek temporal çözünürlüklü dinamik kontrastlı MR] elde olunarak birlikte değerlendirilmektedir [2]. Kılavuz olarak 2015 yılında yayınlanan "Prostate Imaging Repor-ting and Data System, version 2" (PIRADSv2) dokümanı ile protokollerin standardizasyonu için gerekli asgari teknik şartlar ve dikkat edilmesi gereken klinik durumlar ortaya konmuştur [3].…”

Section: Multiparametrik Prostat Mrg Ve 15 T Mrunclassified

“…Günümüzde multiparametrik prostat MRG (mpMRG), klinik olarak anlamlı prostat kanserlerinin belirlenmesi ve hedefli biyopsinin yapılabilmesi için en umut verici görün-tüleme yöntemi konumundadır [2]. mpMRG incelemesi 1,5 Tesla (T) veya 3 T MR cihazlar ile yapılabilir, ancak sağladığı yüksek sinyal/ gürültü oranı nedeniyle 3 T cihazlar daha çok tercih edilmektedir.…”

Section: Introductionunclassified

See 1 more Smart Citation

1,5 Tesla ile Prostat MRG

Yağcı¹,

Fakultesi²

2018

Trd Sem

View full text Add to dashboard Cite

Section: Multiparametrik Prostat Mrg Ve 15 T Mrunclassified

Section: Introductionunclassified

1,5 Tesla ile Prostat MRG

Yağcı¹,

Fakultesi²

2018

Trd Sem

View full text Add to dashboard Cite

“…Diffusion-weighted magnetic resonance imaging (DWI) is a noninvasive, radiation-free tool that does not require the use of exogenous contrast agents, is accessible, and is easy to incorporate into the clinical routine. Over the last decade, DWI has demonstrated good diagnostic performance in multifarious tumors of various etiologies (10)(11)(12)(13)(14) . The aim of this study was to determine the performance of DWI in distinguishing between malignant and benign thoracic lymph nodes.…”

Section: Introductionmentioning

confidence: 99%

Diffusion-weighted magnetic resonance imaging for differentiating between benign and malignant thoracic lymph nodes: a meta-analysis

et al. 2021

View full text Add to dashboard Cite

Objective: To establish the diagnostic performance of diffusion-weighted magnetic resonance imaging (DWI) in discriminating malignant from non-malignant thoracic lymph nodes. Materials and Methods: This was a meta-analysis involving systematic searches of the MEDLINE, EMBASE, and Web of Science databases up through April 2020. Studies reporting thoracic DWI and lymph node evaluation were included. The pooled sensitivity, specificity, diagnostic odds ratio, positive predictive value, negative predictive value, and area under the receiver operating characteristic curve (AUC) were calculated. Results: We evaluated six studies, involving a collective total of 356 mediastinal lymph nodes in 214 patients. Thoracic DWI had a pooled sensitivity and specificity of 92% (95% confidence interval [95% CI]: 71-98%) and 93% (95% CI: 79-98%), respectively. The positive and negative likelihood ratios were 13.2 (95% CI: 4.0-43.8) and 0.09 (95% CI: 0.02-0.36), respectively. The diagnostic odds ratio was 149 (95% CI: 18-1,243), and the AUC was 0.97 (95% CI: 0.95-0.98). Conclusion: DWI is a reproducible technique and has demonstrated high accuracy for differentiating between malignant and benign states in thoracic lymph nodes.

show abstract

“…One of the main issues is the difficulty to discriminate between healthy, benign, and malignant prostatic tissues. Furthermore, other conditions often associated with the disease (eg, prostatitis, atrophy, or hemorrhages) may affect the signal intensity, therefore compromising the overall reliability of the diagnosis . Although alternative MRI‐based diagnostic tools were already proposed, a possible way to overcome these limitations could be to support the readout from T 2w images with information achievable from T 1w images acquired after the injection of PCa‐specific molecular MRI agents.…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, other conditions often associated with the disease (eg, prostatitis, atrophy, or hemorrhages) may affect the signal intensity, therefore compromising the overall reliability of the diagnosis. 11 Although alternative MRI-based diagnostic tools were already proposed, 12 a possible way to overcome these limitations could be to support the readout from T 2w images with information achievable from T 1w images acquired after the injection of PCa-specific molecular MRI agents. Indeed, the use of efficient targeted probes that can specifically reach the tumor could directly and uniquely image the tumor tissue.…”

Section: Introductionmentioning

confidence: 99%

An efficient MRI agent targeting extracellular markers in prostate adenocarcinoma

Pagoto

Tripepi

Stefanìa

et al. 2018

Magnetic Resonance in Med

View full text Add to dashboard Cite

Purpose Prostate cancer (PCa) is the most widespread tumor affecting males in Western countries. We propose a novel MRI molecular tetrameric probe based on the heptadentate gadolinium (Gd)‐AAZTA (6‐amino‐6‐methylperhydro‐1,4‐diazepinetetraacetic acid) that is able to in vivo detect PCa through the recognition of the fibrin–fibronectin (FB–FN) complex. Methods The peptide CREKA (Cys‐Arg‐Glu‐Lys‐Ala), targeting the FB–FN complex in the reactive stroma of the tumor, was synthesized by solid phase peptide synthesis (SPPS) and conjugated to the tetramer dL‐(Gd‐AAZTA)4. The resulting probe was characterized by 1H relaxometry, tested in vitro on FB clots and in vivo on an orthotopic mouse model of PCa. Results CREKA‐dL‐(Gd‐AAZTA)4 showed a remarkable relaxivity of 18.2 mMGd-1s−1 (0.47 T, 25°C) because of the presence of 2 water molecules (q = 2) in the inner coordination sphere of each Gd3+ ion, whose rotational motion (τR) is lengthened as the result of the relatively high molecular weight. The probe displayed a detectable affinity for plasma‐derived FB clots. On intravenous injection of the probe in an orthotopic mouse model of PCa, a significant increase in the prostate T1 contrast (~40%) was observed. The MRI signal appears statistically higher either with respect to the one observed for the control probes and to the one detected when CREKA‐dL‐(Gd‐AAZTA)4 was administered to healthy animals. Conclusions This study demonstrated the ability of the CREKA‐dL‐(Gd‐AAZTA)4 probe to specifically localize in prostate tumor after injection. The high relaxivity of the probe allows the reduction of the injected dose to 20 µmolGd/kg, yielding a good in vivo contrast enhancement in the region of prostate tumor.

show abstract

Evaluating the Role of mpMRI in Prostate Cancer Assessment

Cited by 14 publications

References 84 publications

1,5 Tesla ile Prostat MRG

1,5 Tesla ile Prostat MRG

Diffusion-weighted magnetic resonance imaging for differentiating between benign and malignant thoracic lymph nodes: a meta-analysis

An efficient MRI agent targeting extracellular markers in prostate adenocarcinoma

Contact Info

Product

Resources

About